{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:33:16Z","timestamp":1784752396739,"version":"3.55.0"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,6,26]],"date-time":"2014-06-26T00:00:00Z","timestamp":1403740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>Consideration of the safety of liver transaminases monitoring every 12\u00a0weeks in patients with inflammatory connective tissue disorders who are treated with methotrexate (<jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a retrospective study, the data from rheumatic patients receiving <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content> were analyzed. Alanine aminotransferase (<jats:styled-content style=\"fixed-case\">ALT<\/jats:styled-content>) and aspartate aminotransferase (<jats:styled-content style=\"fixed-case\">AST<\/jats:styled-content>) were measured every 12\u00a0weeks. Based on the physician's final decision about the continuation of <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content>, the patients were classified into one of the following groups: continuation of <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content> without <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content> dose reduction, <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content> dose reduction, <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content> discontinuation due to liver complication and <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content> discontinuation due to other reasons.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 809 patients who were on <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content> were included in the study. The mean follow\u2010up duration and the mean duration of treatment with <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content> were 31.22 and 19.76\u00a0months, respectively. The mean accumulation dose of <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content> was 865.85\u00a0mg. Due to the increase in the level of transaminases in 3.2% of the patients, <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content> dose was reduced; and in 1.1% of the cases it was temporarily discontinued. In the follow\u2010up of the patients with elevated transaminases, they returned to normal limits in 99.5% of patients; and only in four cases (0.5%) they remained elevated and <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content> was discontinued. The probability of the patients remaining on <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content> for 5\u00a0years without discontinuation for liver complications was 98.5%<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Liver transaminase monitoring every 12\u00a0weeks for <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content>\u2010treated patients is safe.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.12416","type":"journal-article","created":{"date-parts":[[2014,6,26]],"date-time":"2014-06-26T11:09:12Z","timestamp":1403780952000},"page":"646-652","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety of less frequent monitoring of liver transaminases levels in rheumatic patients treated with low\u2010dose methotrexate"],"prefix":"10.1111","volume":"17","author":[{"given":"Alireza","family":"Khabbazi","sequence":"first","affiliation":[{"name":"Connective Tissue Diseases Research Center Tabriz University of Medical Sciences Tabriz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sousan","family":"Kolahi","sequence":"additional","affiliation":[{"name":"Connective Tissue Diseases Research Center Tabriz University of Medical Sciences Tabriz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Dastgiri","sequence":"additional","affiliation":[{"name":"Health Services Management Research Centre Tabriz University of Medical Sciences Tabriz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrzad","family":"Hajialiloo","sequence":"additional","affiliation":[{"name":"Connective Tissue Diseases Research Center Tabriz University of Medical Sciences Tabriz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahshid","family":"Nazeri","sequence":"additional","affiliation":[{"name":"Connective Tissue Diseases Research Center Tabriz University of Medical Sciences Tabriz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Nazeri","sequence":"additional","affiliation":[{"name":"Connective Tissue Diseases Research Center Tabriz University of Medical Sciences Tabriz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arefe","family":"Sheikholeslami Salmasi","sequence":"additional","affiliation":[{"name":"Connective Tissue Diseases Research Center Tabriz University of Medical Sciences Tabriz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevda","family":"Gader","sequence":"additional","affiliation":[{"name":"Connective Tissue Diseases Research Center Tabriz University of Medical Sciences Tabriz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shagayegh","family":"Bak Mohammad Zadeh","sequence":"additional","affiliation":[{"name":"Connective Tissue Diseases Research Center Tabriz University of Medical Sciences Tabriz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisan","family":"Ghasemi","sequence":"additional","affiliation":[{"name":"Connective Tissue Diseases Research Center Tabriz University of Medical Sciences Tabriz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arezu","family":"Poormohammad","sequence":"additional","affiliation":[{"name":"Connective Tissue Diseases Research Center Tabriz University of Medical Sciences Tabriz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,6,26]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200002)43:2<464::AID-ANR30>3.0.CO;2-U"},{"issue":"12","key":"e_1_2_7_3_1","first-page":"2521","article-title":"Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients","volume":"29","author":"Sokka T","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep176"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101378"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350203"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.093690"},{"issue":"6","key":"e_1_2_7_8_1","first-page":"1017","article-title":"Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature","volume":"27","author":"Visser K","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310203"},{"issue":"4","key":"e_1_2_7_10_1","first-page":"517","article-title":"Methotrexate use in rheumatoid arthritis is associated with few clinically significant liver function test abnormalities","volume":"23","author":"Yazici Y","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"e_1_2_7_11_1","first-page":"1850","article-title":"Adverse effects of low dose methotrexate therapy in rheumatoid arthritis","volume":"20","author":"McKendry RJ","year":"1993","journal-title":"J Rheumatol"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/anr.1780320202"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380814"},{"issue":"12","key":"e_1_2_7_14_1","first-page":"1628","article-title":"Adverse experience with methotrexate during 176\u00a0weeks of a longterm prospective trial in patients with rheumatoid arthritis","volume":"17","author":"Furst DE","year":"1990","journal-title":"J Rheumatol"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370304"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360307"},{"issue":"2","key":"e_1_2_7_17_1","first-page":"229","article-title":"Clinical liver disease in patients with rheumatoid arthritis taking methotrexate","volume":"19","author":"Phillips CA","year":"1992","journal-title":"J Rheumatol"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(05)80060-9"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11277"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2006.01.007"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-195102000-00009"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.3.338"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.023408"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/anr.1780320603"},{"issue":"4","key":"e_1_2_7_25_1","first-page":"261","article-title":"Safety of methotrexate in rheumatoid arthritis: a retrospective cohort study in clinical practice","volume":"58","author":"La MG","year":"2006","journal-title":"Reumatismo"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-2136-8"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12416","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.12416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T08:52:03Z","timestamp":1695545523000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.12416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,26]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1111\/1756-185X.12416"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.12416","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,26]]},"assertion":[{"value":"2014-06-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}